Replies to post #143 on Equity Field Notes from temporal sources

[DanWebzster]

ARWR recently refined its pipeline by clarifying that its preclinical Aro-Lung1 program is a cystic Fibrosis treatment.

Partnered program with AMGN may gnerate a progress milestone payment in 2018.

raised cash EOY/17 to bring cash to ~$100mn. At present burn rate, this would last midway into 2019.

There's really not much to see here at this point.